Cogito: a turnkey platform to quickly build digital therapeutics for substance use disorders
Official title: Cogito: A Turnkey Solution for Rapidly Developing, Evaluating, Deploying, and Scaling Digital Therapeutics
Run by Square2 Systems, Inc. · NCT07104396 · Data updated 2026-11-12
This project will test whether PhD- or MD-level SUD researchers can easily create and customize digital therapeutic content for substance use disorders using the Cogito drag-and-drop platform.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Square2 Systems, Inc. Industry-sponsored |
| Locations | 1 site (Hanover, New Hampshire) |
| Status | Recruiting |
| Started | July 2, 2025 |
| Main results expected | August 31, 2025 |
| Study ends | August 31, 2025 |
| Registry record updated | August 11, 2025 |
| Trial ID | NCT07104396 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are PhD- or MD-level scientists (or equivalent) at the postdoctoral level or higher who are trained in SUD research and have a stated interest in digital therapeutics for SUDs.
✕Probably not a fit
People who are not researchers (or who lack SUD research training), are under 18, or do not have an interest in digital therapeutics are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational usability study asks experienced SUD researchers to use the Cogito platform to build sample guides, activities, and surveys via an interactive tutorial and a guided "functionality scavenger hunt." Participants complete tasks within the platform and then fill out surveys to provide structured feedback on usability and functionality. The goal is to identify usability issues and improvement opportunities for Cogito when used to create digital therapeutics for substance use disorders. The study is sponsored by Square2 Systems with collaboration from NIDA and conducted at Square2 Systems in Hanover, New Hampshire.
Why it matters
Potential benefit: If successful, Cogito could lower the technical barrier and speed development of evidence-based digital therapeutics for SUDs, enabling more rapid deployment and iteration of behavioral interventions.
How similar studies have gone: Usability studies of other digital health authoring tools have shown feasibility and helpful feedback, but Cogito's turnkey drag-and-drop approach for SUD-specific digital therapeutics represents a novel, initially untested implementation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years * PhD and/or MD-level (or equivalent) scientists at academic institutions or digital health companies at the level of Post-doctoral Fellow or higher. * Training or trained in substance use disorder (SUDs) research. * Must state a specific interest in digital therapeutics for SUDs. Exclusion Criteria: * Those who do not meet inclusion criteria.
Where it's running
-
Square 2 Systems
Hanover, New Hampshire, United States Recruiting
Study contacts
- Study coordinator: Square2 Systems
- Phone: (802) 526-4608
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.